FI924069A - Terapeutiskt anvaendbara peptider och peptidfragment - Google Patents

Terapeutiskt anvaendbara peptider och peptidfragment Download PDF

Info

Publication number
FI924069A
FI924069A FI924069A FI924069A FI924069A FI 924069 A FI924069 A FI 924069A FI 924069 A FI924069 A FI 924069A FI 924069 A FI924069 A FI 924069A FI 924069 A FI924069 A FI 924069A
Authority
FI
Finland
Prior art keywords
peptidfragment
peptider
och
terapeutiskt anvaendbara
terapeutiskt
Prior art date
Application number
FI924069A
Other languages
English (en)
Other versions
FI108139B (fi
FI924069A0 (fi
Inventor
Gustav Gaudernack
Tobias Gedde-Dahl
Jon Amund Eriksen
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of FI924069A0 publication Critical patent/FI924069A0/fi
Publication of FI924069A publication Critical patent/FI924069A/fi
Application granted granted Critical
Publication of FI108139B publication Critical patent/FI108139B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI924069A 1991-02-26 1992-09-11 Menetelmä terapeuttisesti käyttökelpoisen peptidin valmistamiseksi FI108139B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9103974 1991-02-26
GB919103974A GB9103974D0 (en) 1991-02-26 1991-02-26 Therapeutically useful peptides or peptide fragments
PCT/NO1992/000032 WO1992014756A1 (en) 1991-02-26 1992-02-21 Therapeutically useful peptides and peptides fragments
NO9200032 1992-02-21

Publications (3)

Publication Number Publication Date
FI924069A0 FI924069A0 (fi) 1992-09-11
FI924069A true FI924069A (fi) 1992-09-11
FI108139B FI108139B (fi) 2001-11-30

Family

ID=10690575

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924069A FI108139B (fi) 1991-02-26 1992-09-11 Menetelmä terapeuttisesti käyttökelpoisen peptidin valmistamiseksi

Country Status (14)

Country Link
US (1) US5961978A (fi)
EP (1) EP0529023B1 (fi)
AT (1) ATE181337T1 (fi)
AU (1) AU660452B2 (fi)
CA (1) CA2077537C (fi)
DE (1) DE69229428T2 (fi)
DK (1) DK0529023T3 (fi)
ES (1) ES2134797T3 (fi)
FI (1) FI108139B (fi)
GB (2) GB9103974D0 (fi)
GR (1) GR3031234T3 (fi)
HK (1) HK1011370A1 (fi)
NO (1) NO923953L (fi)
WO (1) WO1992014756A1 (fi)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614531A1 (de) * 1992-09-30 1994-09-14 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts NACHWEISVERFAHREN FÜR p53-SPEZIFISCHE ANTIKÖRPER
EP0692973A1 (en) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
AT399656B (de) * 1993-03-19 1995-06-26 Boehringer Ingelheim Int Verfahren zur herstellung von krebsvakzinen
GB9422814D0 (en) * 1994-11-11 1995-01-04 Medinnova Sf Chemical method
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US6365151B1 (en) 1996-01-19 2002-04-02 Philadelphia Health And Educational Corporation Cellular immunogens comprising cognate proto-oxogenes
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
DE69714033T2 (de) 1996-04-19 2003-02-13 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten
US6069229A (en) * 1997-03-07 2000-05-30 Schering Corporation Mammalian proteinases; oxidoreductases; related reagents
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
DE60326931D1 (de) * 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR101241272B1 (ko) 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
JP2008516610A (ja) * 2004-10-18 2008-05-22 グローブイミューン，インコーポレイテッド 酵母を用いた慢性ｃ型肝炎感染の治療
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
KR20090008290A (ko) * 2006-03-27 2009-01-21 글로브이뮨 Ｒａｓ 돌연변이와 그에 관련된 조성물 및 방법
US20080079547A1 (en) * 2006-09-29 2008-04-03 Sensormatic Electronics Corporation Radio frequency identification reader having a signal canceller and method thereof
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
SI3079715T1 (en) 2013-12-09 2018-08-31 Targovax Asa A mixture of peptides
US9757439B2 (en) 2014-05-06 2017-09-12 Targovax Asa Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
US11771749B2 (en) 2017-02-03 2023-10-03 The Medical College Of Wisconsin, Inc. KRAS peptide vaccine compositions and method of use
CA3065325A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
CN112118847B (zh) * 2018-03-02 2024-05-28 伊莱西奥治疗有限公司 包含突变kras序列和脂质的化合物及其用途
CN114573688A (zh) * 2018-10-19 2022-06-03 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1252046A (en) * 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
US4898932A (en) * 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
CA1296660C (en) * 1985-01-29 1992-03-03 Walter P. Carney Monoclonal antibody against a ras oncogene p21 related dodecapeptide
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
CA1339069C (en) * 1987-11-09 1997-07-29 Henry Lee Niman Polypeptide-induced monoclonal receptors to protein ligand
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
EP0370012A1 (en) * 1988-03-08 1990-05-30 E.I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
ATE258686T1 (de) * 1988-04-22 2004-02-15 Bayer Ag Nachweis, quantifizierung und klassifizierung von ras-proteinen in körperflüssigkeiten und geweben
DE68928470T2 (de) * 1988-08-12 1998-04-16 Ligand Pharm Inc Polypeptid-induzierte monoklonale Rezeptoren gegen Proteinliganden
DK0617124T3 (da) * 1990-01-26 1999-12-06 Washington Res Found Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster

Also Published As

Publication number Publication date
EP0529023B1 (en) 1999-06-16
EP0529023A1 (en) 1993-03-03
NO923953L (no) 1993-03-26
AU1272992A (en) 1992-09-15
ATE181337T1 (de) 1999-07-15
WO1992014756A1 (en) 1992-09-03
ES2134797T3 (es) 1999-10-16
FI108139B (fi) 2001-11-30
GB2253211A (en) 1992-09-02
DK0529023T3 (da) 2000-01-17
AU660452B2 (en) 1995-06-29
GB9103974D0 (en) 1991-04-10
FI924069A0 (fi) 1992-09-11
DE69229428T2 (de) 2000-06-29
US5961978A (en) 1999-10-05
DE69229428D1 (de) 1999-07-22
GB9204098D0 (en) 1992-04-08
CA2077537A1 (en) 1992-08-27
GR3031234T3 (en) 1999-12-31
NO923953D0 (no) 1992-10-12
HK1011370A1 (en) 1999-07-09
CA2077537C (en) 2000-06-13

Similar Documents

Publication Publication Date Title
FI924069A (fi) Terapeutiskt anvaendbara peptider och peptidfragment
DK0585943T3 (da) Opløselige ligander for CD40
DK0604418T3 (da) Isolerede viralproteincytokinantagonister
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
ATE212540T1 (de) Antitumorvakzine
EP0541692A4 (en) Herpes simplex virus vp16 vaccines
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
GB0004576D0 (en) Proteins
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
ATE69549T1 (de) Erzeugnisse, enthaltend gallopamil und prazosin.
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
PT1173481E (pt) Citoquinas inactivas para a imunização

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: GEMVAX AS

Free format text: GEMVAX AS